By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
Medicines can cause serious side effects in infants and young children. Only medications designed specifically for them can be taken by them.
Babies should not take many medications that adults can take. This is so because newborns are significantly smaller and have distinct responses to medications.
Children’s minor diseases like colds and coughs don’t usually require medication. The best option is a sugar-free variety. Children’s teeth can suffer from medications with sugar in them.
The India baby medicine market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
The FDA releases Dupixent (dupilumab) as the first biologic treatment for children with moderate-to-severe atopic dermatitis, aged 6 months to 5 years.
The sole and first biologic drug, Dupixent, has been licensed to treat mild to moderately severe atopic dermatitis in children and adults.
In a Phase 3 trial, children treated with Dupixent with topical corticosteroids (TCS) had cleaner skin and considerably less itching at week 16 compared to TCS alone.The 52-week open-label extension trial’s long-term safety findings in this age range support Dupixent’s well-known safety profile as seen in all other approved age groups.
Dupixent can be administered at a clinic or at home with self-administration after training by a healthcare professional. It is meant to be used under the supervision of a healthcare expert.
If given at home, Dupixent should be provided to children under the age of 12 by a caregiver. Initial lab testing and continuing lab monitoring are not needed with Dupixent.
Dupixent is a completely human monoclonal antibody that does not suppress the immune system but instead blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways.
Phase 3 trials of the Dupixent development program have demonstrated a significant clinical benefit and a reduction in type 2 inflammation, demonstrating that IL-4 and IL-13 are important and central drivers of the type 2 inflammation that is a significant contributor to a number of connected and frequently comorbid diseases.
